AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16439720 — intervention group
Group type: EXPERIMENTAL
Intervention: Heliox28 (72% He/28% O2)
Number of subjects: 82
Study 16439720 — intervention group
Group type: EXPERIMENTAL
Intervention: Heliox21 (79% He/21% O2)
Number of subjects: 82
Study 16439720 — intervention group
Group type: COMPARATOR
Intervention: Oxygen28 (72% N2/28% O2)
Number of subjects: 82
Study 16439720 — intervention group
Group type: COMPARATOR
Intervention: Medical air (79% N2/21% O2)
Number of subjects: 82
Study 12630026 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose hepatitis B virus vaccination (40 mcg) with a shortened immunization schedule
Number of subjects: 138
Study 11203962 — intervention group
Group type: EXPERIMENTAL
Intervention: SureFil and Prime & Bond NT
Number of subjects: 60
Study 11203962 — intervention group
Group type: EXPERIMENTAL
Intervention: SureFil and PQ1
Number of subjects: 60
Study 11203962 — intervention group
Group type: EXPERIMENTAL
Intervention: SureFil, PermaFlow, and PQ1
Number of subjects: 60
Study 11203962 — intervention group
Group type: COMPARATOR
Intervention: Heliomolar and Syntac Single‐Component
Number of subjects: 60
Study 9359543 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual coil transvenous lead
Number of subjects: 21
Study 9359543 — intervention group
Group type: EXPERIMENTAL
Intervention: Unipolar configuration (distal right ventricular coil and pectoral pulse generator shell)
Number of subjects: 21
Study 9359543 — intervention group
Group type: EXPERIMENTAL
Intervention: Triad configuration (all 3 components)
Number of subjects: 21
Study 9359543 — intervention group
Group type: COMPARATOR
Intervention: Triad configuration
Number of subjects: 21
Study 9359543 — intervention group
Group type: COMPARATOR
Intervention: Unipolar configuration
Number of subjects: 21
Study 7694528 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane anesthesia with epinephrine doses of 7.0-13.0 micrograms/kg
Number of subjects: 36
Study 7694528 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane anesthesia with epinephrine doses of 7.0-13.0 micrograms/kg
Number of subjects: 36
Study 7694528 — intervention group
Group type: EXPERIMENTAL
Intervention: Both anesthetic groups with epinephrine doses less than 7.0 micrograms/kg
Number of subjects: 36
Study 4053529 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium diclofenac (100 mg tablets of slow-release diclofenac)
Number of subjects: 25
Study 29861177 — intervention group
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (PCV13)
Number of subjects: 0
Study 30295803 — intervention group
Group type: EXPERIMENTAL
Intervention: Text-messaging adherence support
Number of subjects: 181
Study 30295803 — intervention group
Group type: COMPARATOR
Intervention: Standard of care for PrEP adherence
Number of subjects: 181
Study 27575673 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy massage
Number of subjects: 90
Study 27575673 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation aromatherapy
Number of subjects: 90
Study 27575673 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study 25322540 — intervention group
Group type: EXPERIMENTAL
Intervention: Membrane sweeping (Sweeping Group)
Number of subjects: 140
Study 25322540 — intervention group
Group type: COMPARATOR
Intervention: No membrane sweeping (Control Group)
Number of subjects: 140
Study 21993599 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful ablation
Number of subjects: 38
Study 21993599 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease in NT‐pro‐BNP >25% from baseline
Number of subjects: 38
Study 19885712 — intervention group
Group type: EXPERIMENTAL
Intervention: Alumina matrix composite femoral heads articulating on alumina liners
Number of subjects: 65
Study 19885712 — intervention group
Group type: COMPARATOR
Intervention: Zirconia femoral heads on polyethylene liners
Number of subjects: 65
Study 17919556 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 382
Study 17919556 — intervention group
Group type: EXPERIMENTAL
Intervention: Travoprost
Number of subjects: 382
Study 17919556 — intervention group
Group type: COMPARATOR
Intervention: Bayesian network prediction
Number of subjects: 382
Study 16195897 — intervention group
Group type: EXPERIMENTAL
Intervention: PMR plus medical management
Number of subjects: 73
Study 16195897 — intervention group
Group type: COMPARATOR
Intervention: Medical management alone
Number of subjects: 73
Study 11135723 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release hydromorphone (8, 16, and 32 mg)
Number of subjects: 12
Study 11135723 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release hydromorphone (8 mg)
Number of subjects: 12
Study 11135723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9701300 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructor-taught CPR class
Number of subjects: 480
Study 9701300 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructor-taught CPR class followed by a social support intervention
Number of subjects: 480
Study 9701300 — intervention group
Group type: COMPARATOR
Intervention: Self-training video module
Number of subjects: 480
Study 7857346 — intervention group
Group type: EXPERIMENTAL
Intervention: pidotimod 50 mg, 100 mg, 200 mg twice a day
Number of subjects: 43
Study 7857346 — intervention group
Group type: EXPERIMENTAL
Intervention: pidotimod (any dosage)
Number of subjects: 43
Study 7857346 — intervention group
Group type: EXPERIMENTAL
Intervention: pidotimod 400 mg/day
Number of subjects: 43
Study 7857346 — intervention group
Group type: COMPARATOR
Intervention: physiological saline
Number of subjects: 43
Study 2706957 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 widely used surfactants and 1 solubilizer applied in aqueous solutions of 12.5 millimoles/l for 45 min twice daily for 3 weeks
Number of subjects: 0
Study 2706957 — intervention group
Group type: EXPERIMENTAL
Intervention: TEWL measurements
Number of subjects: 0
Study 2706957 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual scoring system
Number of subjects: 0
Study 802649 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-methyldopa
Number of subjects: 41
Study 802649 — intervention group
Group type: EXPERIMENTAL
Intervention: guanethidine
Number of subjects: 41
Study 802649 — intervention group
Group type: EXPERIMENTAL
Intervention: clonidine
Number of subjects: 41
Study 802649 — intervention group
Group type: EXPERIMENTAL
Intervention: reserpine
Number of subjects: 41
Study 29748900 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth Familias Unidas
Number of subjects: 230
Study 29748900 — intervention group
Group type: COMPARATOR
Intervention: Prevention as usual
Number of subjects: 230
Study 27145774 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicruciate-retaining total knee arthroplasty (BCR group)
Number of subjects: 60
Study 27145774 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial unicompartmental knee arthroplasty (UKA group)
Number of subjects: 60
Study 27145774 — intervention group
Group type: COMPARATOR
Intervention: Posterior stabilized total knee arthroplasty (PS group)
Number of subjects: 60
Study 26411223 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound monitored TCRS
Number of subjects: 126
Study 26411223 — intervention group
Group type: COMPARATOR
Intervention: Laparoscope monitored TCRS
Number of subjects: 126
Study 23041968 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy followed by 30 min of exercise
Number of subjects: 12
Study 23041968 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy followed by 30 min of rest
Number of subjects: 12
Study 21304253 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning medication (50 mg of naftopidil once a day after breakfast for 8 weeks)
Number of subjects: 100
Study 21304253 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening medication (50 mg of naftopidil once a day after supper for 8 weeks)
Number of subjects: 100
Study 21304253 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning medication (50 mg of naftopidil)
Number of subjects: 100
Study 21304253 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening medication (50 mg of naftopidil)
Number of subjects: 100
Study 19736473 — intervention group
Group type: COMPARATOR
Intervention: Folic acid (FA), 5 mg/day
Number of subjects: 36
Study 19736473 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (FA), 5 mg/day + vitamin B12, 1 mg/day
Number of subjects: 36
Study 19736473 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (FA), 15 mg/day
Number of subjects: 36
Study 19736473 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (FA), 15 mg/day + vitamin B12, 1 mg/day
Number of subjects: 36
Study 17009077 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 to 100 mg once daily)
Number of subjects: 96
Study 17009077 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 15231472 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine heart model (BHM) and 2D anatomic pictures of human hearts (Group 2)
Number of subjects: 35
Study 15231472 — intervention group
Group type: COMPARATOR
Intervention: 2D anatomic pictures of human hearts (Group 1)
Number of subjects: 35
Study 11106014 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine-thymol varnish application every 3 months
Number of subjects: 29
Study 11106014 — intervention group
Group type: COMPARATOR
Intervention: Fluoride gel only (Control)
Number of subjects: 29
Study 9645783 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted learning (CAL)
Number of subjects: 82
Study 9645783 — intervention group
Group type: COMPARATOR
Intervention: Lecture and feedback seminar (LFS)
Number of subjects: 82
Study 9508950 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial saliva substitute
Number of subjects: 25
Study 3335295 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate, amoxicillin, and the combination of colloidal bismuth subcitrate and amoxicillin
Number of subjects: 337
Study 3335295 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin monotherapy
Number of subjects: 337
Study 3335295 — intervention group
Group type: COMPARATOR
Intervention: C. pyloridis positive culture
Number of subjects: 337
Study 3335295 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial eradication of C. pyloridis
Number of subjects: 337
Study 3335295 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful eradication of C. pyloridis
Number of subjects: 337
Study 31805983 — intervention group
Group type: EXPERIMENTAL
Intervention: Modification of the style of the participant information leaflet (PIL)
Number of subjects: 0
Study 31805983 — intervention group
Group type: COMPARATOR
Intervention: Delaying provision of the full PIL until the potential participant attended the trial clinic
Number of subjects: 0
Study 31805983 — intervention group
Group type: COMPARATOR
Intervention: Modification of the style of the PIL
Number of subjects: 0
Study 28302406 — intervention group
Group type: EXPERIMENTAL
Intervention: Microalgae oil (2.1 g DHA/d)
Number of subjects: 38
Study 28302406 — intervention group
Group type: COMPARATOR
Intervention: Sunflower oil (placebo)
Number of subjects: 38
Study 26782853 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 IU/d of vitamin D3
Number of subjects: 81
Study 26782853 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 IU/d of vitamin D3
Number of subjects: 81
Study 26782853 — intervention group
Group type: EXPERIMENTAL
Intervention: 4000 IU/d of vitamin D3
Number of subjects: 81
Study 26782853 — intervention group
Group type: EXPERIMENTAL
Intervention: 50000 IU/wk of vitamin D3
Number of subjects: 81
Study 26782853 — intervention group
Group type: EXPERIMENTAL
Intervention: Total and free 25(OH)D
Number of subjects: 81
Study 24821095 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengthening Families Program plus Life Skills Training (LST)
Number of subjects: 36
Study 24821095 — intervention group
Group type: EXPERIMENTAL
Intervention: Life Skills Training (LST) only
Number of subjects: 36
Study 24821095 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 36
Study 21369788 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased sunlight exposure (additional 30‐40 min/day in the early morning) with calcium supplementation (600 mg/day)
Number of subjects: 602
Study 21369788 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased sunlight exposure (additional 30‐40 min/day in the early morning) without calcium supplementation
Number of subjects: 602
Study 21369788 — intervention group
Group type: COMPARATOR
Intervention: Control group (neither increased sunlight exposure nor calcium supplementation)
Number of subjects: 602
Study 19576114 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dosage targeting goal (SDTG) group - atorvastatin 10 mg/d
Number of subjects: 102
Study 19576114 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive dosage targeting goal (IDTG) group - atorvastatin 20-80 mg/d
Number of subjects: 102
Study 19576114 — intervention group
Group type: COMPARATOR
Intervention: Standard dosage non-targeting goal (SDNTG) group - atorvastatin 10 mg/d without targeting goal
Number of subjects: 102
Study 19576114 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 102
Study 19576114 — intervention group
Group type: EXPERIMENTAL
Intervention: All dosages of atorvastatin (10 mg, 20 mg, 40 mg, 80 mg)
Number of subjects: 102
Study 17767636 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-ketamine (PK) - 1 mg x kg(‐1) ketamine + 1.2 mg x kg(‐1) propofol
Number of subjects: 90
Study 17767636 — intervention group
Group type: COMPARATOR
Intervention: Propofol-fentanyl (PF) - 1 microg x kg(‐1) fentanyl + 1.2 mg x kg(‐1) propofol
Number of subjects: 90
Study 17767636 — intervention group
Group type: COMPARATOR
Intervention: Propofol-fentanyl (PF)
Number of subjects: 90
Study 14687871 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (5-25 mg/day)
Number of subjects: 147
Study 14687871 — intervention group
Group type: COMPARATOR
Intervention: Clozapine (100-500 mg/day)
Number of subjects: 147
Study 14687871 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 147
Study 14687871 — intervention group
Group type: COMPARATOR
Intervention: Clozapine
Number of subjects: 147
Study 12405466 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine dissolved in artificial saliva administered in a mouth spray
Number of subjects: 23
Study 12405466 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 12405466 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine
Number of subjects: 23
Study 12405466 — intervention group
Group type: COMPARATOR
Intervention: Control medicaments
Number of subjects: 23
Study 9889451 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal letter written in Vietnamese promoting cervical screening
Number of subjects: 689
Study 9889451 — intervention group
Group type: COMPARATOR
Intervention: No personal letter (control group)
Number of subjects: 689
Study 7821274 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g VGB
Number of subjects: 146
Study 7821274 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g VGB
Number of subjects: 146
Study 7821274 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 g VGB
Number of subjects: 146
Study 7821274 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study 2399925 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery condition
Number of subjects: 27
Study 2399925 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 27
Study 96473 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 5 mg i.v. pretreatment
Number of subjects: 10
Study 96473 — intervention group
Group type: COMPARATOR
Intervention: Saline pretreatment (control)
Number of subjects: 10
Study 30765242 — intervention group
Group type: EXPERIMENTAL
Intervention: MMRV (two doses of combined measles-mumps-rubella-varicella vaccine)
Number of subjects: 5803
Study 30765242 — intervention group
Group type: EXPERIMENTAL
Intervention: MMR + V (one dose of live attenuated varicella vaccine after one dose of measles-mumps-rubella vaccine)
Number of subjects: 5803
Study 30765242 — intervention group
Group type: COMPARATOR
Intervention: MMR (two doses of measles-mumps-rubella vaccine)
Number of subjects: 5803
Study 28676211 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab added to pemetrexed/cisplatin (PC) chemotherapy
Number of subjects: 0
Study 28676211 — intervention group
Group type: COMPARATOR
Intervention: Pemetrexed/cisplatin (PC) chemotherapy alone
Number of subjects: 0
Study 26070073 — intervention group
Group type: EXPERIMENTAL
Intervention: Compressive forces of 0, 1, 2 and 3 kg/cm2 for 30 seconds
Number of subjects: 15
Study 26070073 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrared thermography performed 15 minutes after contact with the skin
Number of subjects: 15
Study 26070073 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrared thermography performed within 60 minutes after contact with the skin
Number of subjects: 15
Study 24200199 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose of Bifilact(®) probiotics (1.3 billion CFU, twice a day)
Number of subjects: 246
Study 24200199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 246
Study 24200199 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose of Bifilact(®) probiotics (1.3 billion CFU, twice a day) in patients who had surgery
Number of subjects: 246
Study 24200199 — intervention group
Group type: COMPARATOR
Intervention: Placebo in patients who had surgery
Number of subjects: 246
Study 22596211 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) 200 mg + Methotrexate (MTX)
Number of subjects: 216
Study 22596211 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) + Methotrexate (MTX)
Number of subjects: 216
Study 19058924 — intervention group
Group type: COMPARATOR
Intervention: Non-active control condition (e.g., placebo or attention-only control)
Number of subjects: 0
Study 19058924 — intervention group
Group type: EXPERIMENTAL
Intervention: Validated treatment via a different modality
Number of subjects: 0
Study 19058924 — intervention group
Group type: EXPERIMENTAL
Intervention: Tests of the new treatment as an add-on to standard treatment
Number of subjects: 0
Study 19058924 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of dose-response design
Number of subjects: 0
Study 19058924 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of unequal randomization designs
Number of subjects: 0
Study 19058924 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of stopping rules
Number of subjects: 0
Study 19058924 — intervention group
Group type: EXPERIMENTAL
Intervention: Provision of optimal therapy to those who fail during the study
Number of subjects: 0
Study 19058924 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of the experimental treatment vs. standard treatment
Number of subjects: 0
Study 17160407 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (5 microg twice daily for 4 weeks, then 10 microg thereafter)
Number of subjects: 501
Study 15300911 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC) with 5 min of ischemia and 5 min of reperfusion
Number of subjects: 29
Study 15300911 — intervention group
Group type: COMPARATOR
Intervention: Control group (no IPC)
Number of subjects: 29
Study 12078888 — intervention group
Group type: EXPERIMENTAL
Intervention: MEC
Number of subjects: 355
Study 12078888 — intervention group
Group type: COMPARATOR
Intervention: ABVD
Number of subjects: 355
Study 12078888 — intervention group
Group type: EXPERIMENTAL
Intervention: Stanford V
Number of subjects: 355
Study 12078888 — intervention group
Group type: EXPERIMENTAL
Intervention: All arms
Number of subjects: 355
Study 10420106 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2% + Timolol 0.5%
Number of subjects: 15
Study 10420106 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.5% + Placebo
Number of subjects: 15
Study 7497145 — intervention group
Group type: EXPERIMENTAL
Intervention: Retesting with dietary restrictions after an initial positive Haemoccult screening test
Number of subjects: 35260
Study 7497145 — intervention group
Group type: COMPARATOR
Intervention: Immediate colonoscopy after a positive Haemoccult screening test
Number of subjects: 35260
Study 2301216 — intervention group
Group type: EXPERIMENTAL
Intervention: 65% maximal heart rate
Number of subjects: 49
Study 2301216 — intervention group
Group type: EXPERIMENTAL
Intervention: 75% maximal heart rate
Number of subjects: 49
Study 2301216 — intervention group
Group type: EXPERIMENTAL
Intervention: 85% maximal heart rate
Number of subjects: 49
Study 2301216 — intervention group
Group type: COMPARATOR
Intervention: Control (non-exercise)
Number of subjects: 49
Study 456272 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of 0.25 mg g-strophanthin
Number of subjects: 6
Study 456272 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual administration of 6.0 mg g-strophanthin
Number of subjects: 6
Study 30674348 — intervention group
Group type: EXPERIMENTAL
Intervention: Online self-help program ('Restart') based on cognitive behavioral therapy (CBT)
Number of subjects: 136
Study 30674348 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 136
Study 28497942 — intervention group
Group type: EXPERIMENTAL
Intervention: UpBdResist (upper body resistance exercises followed by 30‐minute cycling at 50%VO2max)
Number of subjects: 16
Study 28497942 — intervention group
Group type: EXPERIMENTAL
Intervention: LwBdResist (lower body resistance exercises followed by 30 minutes on an arm‐ergometer)
Number of subjects: 16
Study 28497942 — intervention group
Group type: EXPERIMENTAL
Intervention: LwBdResist
Number of subjects: 16
Study 28497942 — intervention group
Group type: EXPERIMENTAL
Intervention: UpBdResist
Number of subjects: 16
Study 25687364 — intervention group
Group type: EXPERIMENTAL
Intervention: PCL-FM/MTA direct pulp capping
Number of subjects: 60
Study 25687364 — intervention group
Group type: COMPARATOR
Intervention: MTA direct pulp capping
Number of subjects: 60
Study 23392147 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugared chewing gum (Gum) - instructed to chew 3 times daily for 45 minutes each time for 7 days postoperatively
Number of subjects: 114
Study 23392147 — intervention group
Group type: COMPARATOR
Intervention: No Gum
Number of subjects: 114
Study 21248332 — intervention group
Group type: EXPERIMENTAL
Intervention: TS-11-MG vaccine
Number of subjects: 160
Study 21248332 — intervention group
Group type: COMPARATOR
Intervention: Bacterin + TS-11-MG combined
Number of subjects: 160